Society for Investigative Dermatology | Dermatology Research | Academic Dermatology
This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Sun Pharma Awards
Share |

 

Sun Pharma/SID Mid-Career Awards

Congratulations to the 2019 Sun Pharma/SID Mid-Career Award Recipients!

Bridge Awardees

 

Dawn  Siegel, MD, Medical College of Wisconsin

My research focuses on the discovery of the genetic basis of hemangioma syndromes associated with congenital malformations. In 2006, I founded the PHACE Syndrome International Clinical Registry and Genetic Repository. PHACE is an acronym for Posterior Fossa Anomalies, Hemangiomas, Arterial Anomalies, Cardiac Defects, Eye Anomalies and Sternal Anomalies. In 2013, I was awarded an R01 entitled “Pathogenesis & Natural History in a Longitudinal Hemangioma Syndrome Cohort.” Through this award, I made significant progress in understanding the natural history of PHACE syndrome and generated preliminary data to investigate the genetic basis of PHACE.  I have an established DNA and tissue bank for this cohort. I was awarded a Gabriella Miller Kids First X01 for whole genome sequencing of 100 families. Characterization of genomic alterations in PHACE will lead to better understanding of the pathobiology and subsequently identify predictive factors for long-term morbidity. We will generate fundamental information regarding the pathogenesis of PHACE, which will ultimately uncover new gene targets and pathways that can be used in the development of therapies for infantile hemangioma.

 

Suzanne Cassel, MD, Cedars-Sinai

Currently, the majority of our understanding of innate immune receptors is related to responses to infectious stimuli. While our group has established a role of the NLR family of innate immune receptors in sterile inflammatory responses, my future studies aim to focus on the innate immune response to malignancy, including melanoma. This interaction is remarkably complex, with the tumor at times benefiting from inflammatory responses and at other times being damaged by immune responses. It is also two-way, with the melanoma cells modulating the innate immune cells’ ability to respond to stimuli as well as the innate immune cells having effects directly and indirectly on the melanoma. My long-term career goal is to delineate the complex relationship of innate pattern recognition receptors with melanoma tumorigenesis and progression, and in particular to unharness the specific and directed adaptive immune response against melanoma.

 

 

DESCRIPTION

Sun Pharma/SID Mid-Career Investigator Awards are intended to bridge funding gaps for outstanding mid-career investigative dermatologists.

These awards debuted in 2018, and the number of strong applications exceeded available funding. The SID recognized the importance of these bridge awards and has allocated additional funds for two more awards of $100,000 each.

AWARDS

Based on a generous gift from Sun Pharma, and supplemented by the SID, there will be up to five Bridge Awards of $100,000 each given in 2019 to deserving mid-career investigators in the field of dermatology or cutaneous biology.

Awards are for a period of one year with an option for one renewal.

At least one physician scientist and one PhD cutaneous biologist will be funded.

ELIGIBILITY REQUIREMENTS

Active SID Members who are an MD, DO, PhD, MD/PhD or equivalent, and holding a full-time faculty position at a US Department or Division of Dermatology or equivalent.

Applicant must be mid-career and not qualify as an NIH-defined New Investigator.

Applicant must have previously received NIH R01 funding. Prior Ks and R03s are not eligible.

Applicant must have submitted an NIH R01 within the past 12-months that will not be funded by April 2019. Priority will be given to applications with scores that were close to a fundable score for each particular grant mechanism.

Applicant must not have current research support of more than $100,000 available to their lab after April 30, 2019.

Only applications focused on basic or clinical research seeking new discoveries in the field of dermatology or cutaneous biology will be eligible.

REVIEW

An independent SID Grant Review Committee will select award recipients.

For further information or questions please contact Becky Minnillo

Society for Investigative Dermatology
526 Superior Avenue East, Suite 340
Cleveland, Ohio 4411
4

Tel: 216.579.9300
Fax: 216.579.9333

sid@sidnet.org

The SID mission is to advance the sciences relevant to skin disease through education,

advocacy and scholarly exchange of scientific information.